ArticleClinical lymphoma, myeloma & leukemia2016
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
Article in Clinical lymphoma, myeloma & leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review.PloS one · 2022Pooled it
- Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.PloS one · 2021Pooled it
- Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis.Journal of geriatric oncology · 2020Pooled it
- Current status and research directions in acute myeloid leukemia.Blood cancer journal · 2024Review
- Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.Cancer · 2023Article
- Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy.American journal of hematology · 2022Article
- Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades.Clinical lymphoma, myeloma & leukemia · 2021Review
- Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.Cancer · 2021Review
- Acute myeloid leukemia: current progress and future directions.Blood cancer journal · 2021Review
- American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2020Article
- Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms.Journal of pediatric hematology/oncology · 2018Article
- Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia).Drug design, development and therapy · 2018Review
- Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.Cell cycle (Georgetown, Tex.) · 2018Article
- Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.Cancer · 2017Article
- Acute myeloid leukemia management and research in 2025.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 2 countries.
Funding
Abstract
introductionMost patients with acute myeloid leukemia (AML) age ≥ 60 years are not offered intensive induction because of high mortality. Phase 2 studies of clofarabine plus low-dose cytarabine (CLDA) as frontline therapy for elderly AML patients demonstrated high response and acceptable toxicity. PATIENTS AND
methodsWe hypothesized that induction therapy with CLDA provides equivalent outcomes to but is less toxic than intensive induction in these patients. To test this hypothesis, we conducted a propensity score-matched comparison of AML patients age ≥ 60 years given induction CLDA versus idarubicin and cytarabine (IA). Ninety-five patients in both groups were matched according to their propensity score.
resultsWe did not observe statistically significant differences in response, overall survival, or mortality rate between the two induction regimens. However, CLDA produced significantly fewer grade 3 or worse toxicities (46% for CLDA vs. 62% for IA; P = .03). Furthermore, among responders, the median response duration was significantly longer with CLDA when we censored patients who underwent stem cell transplantation (15.9 months for CLDA vs. 7.0 months for IA; P = .033).
conclusionCompared with intensive induction, CLDA offers equivalent responses and survival but less toxicity in clinically well-matched cohorts of elderly AML patients. Prospective randomized trials to confirm these findings are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.